A Review on Gene Therapy for Cystic Fibrosis
Year: 2024
Type: article
Abstract: Cystic fibrosis is a chronic autosomal recessive disease, and it is caused by the mutations in a single gene encodes the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Even though cystic fibrosis affects multiple organ systems, the majority of CF patients pass away from progressive lung illness, which starts in childhood and is typified by persistent inflammation and bacterial infection. The ∆F508 mutation is present in at least one copy in about 90% of CF patients, but there are hundreds of CFTR mutations that cause various degrees of disease severity. When the CFTR protein isn't working properly, a thick coating of mucus builds up and blocks the intestines, airways, and pancreatic ducts main cause of death. How to treat cystic fibrosis was mostly dealing with the symptoms in order to get over the disease's complications. From the early 2010s onward, the creation of a real treatment has advanced to an advance, such as modulators of tiny molecules and Genetic medicine. The first clinical trials involving CF patients were carried out in 1993 and involved the use of both viral and non-viral gene transfer agentsin the bronchial and nasal airway epithelium. Even though it has steadily increased over the past few decades, people with cystic fibrosis still only live to be about 40 years old. The focus of current treatment guidelines should be on managing symptoms and complications. This article examines describe the current state of the science and recent advancements in CF gene therapy and screening.
Author: Miss. Dhandu pujitha, Dr. C. Bhuvaneswara Rao, Dr. K. Venugopal
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6949555877
FWCI:
Cites:
Cited by:
Related to: